Last reviewed · How we verify
Clopidogrel & Aspirin, Prasugrel & Aspirin
At a glance
| Generic name | Clopidogrel & Aspirin, Prasugrel & Aspirin |
|---|---|
| Sponsor | Baim Institute for Clinical Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- The Switching Antiplatelet-9 (SWAP-9) Study (PHASE4)
- Bariatric Surgery for the Reduction of cArdioVascular Events Randomized Controlled Trial (NA)
- Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) (NA)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: